| Literature DB >> 28635330 |
Grazia R Tundo1,2, Diego Sbardella1,2,3, Chiara Ciaccio1,2, Giuseppe Grasso4,5, Magda Gioia1,2, Andrea Coletta6, Fabio Polticelli7, Donato Di Pierro1,2, Danilo Milardi5, Peter Van Endert8, Stefano Marini1,2,3, Massimo Coletta1,2,3.
Abstract
Insulin-degrading enzyme (IDE) is a ubiquitous zinc peptidase of the inverzincin family, which has been initially discovered as the enzyme responsible for insulin catabolism; therefore, its involvement in the onset of diabetes has been largely investigated. However, further studies on IDE unraveled its ability to degrade several other polypeptides, such as β-amyloid, amylin, and glucagon, envisaging the possible implication of IDE dys-regulation in the "aggregopathies" and, in particular, in neurodegenerative diseases. Over the last decade, a novel scenario on IDE biology has emerged, pointing out a multi-functional role of this enzyme in several basic cellular processes. In particular, latest advances indicate that IDE behaves as a heat shock protein and modulates the ubiquitin-proteasome system, suggesting a major implication in proteins turnover and cell homeostasis. In addition, recent observations have highlighted that the regulation of glucose metabolism by IDE is not merely based on its largely proposed role in the degradation of insulin in vivo. There is increasing evidence that improper IDE function, regulation, or trafficking might contribute to the etiology of metabolic diseases. In addition, the enzymatic activity of IDE is affected by metals levels, thus suggesting a role also in the metal homeostasis (metallostasis), which is thought to be tightly linked to the malfunction of the "quality control" machinery of the cell. Focusing on the physiological role of IDE, we will address a comprehensive vision of the very complex scenario in which IDE takes part, outlining its crucial role in interconnecting several relevant cellular processes.Entities:
Keywords: Alzheimer’s disease; cell homeostasis; heat shock proteins; insulin-degrading enzyme; oxidized proteins turnover; type 2 diabetes; ubiquitin proteasome system
Mesh:
Substances:
Year: 2017 PMID: 28635330 DOI: 10.1080/10409238.2017.1337707
Source DB: PubMed Journal: Crit Rev Biochem Mol Biol ISSN: 1040-9238 Impact factor: 8.250